Cell Biology

CellExSys Patents T Cell Expansion Technology

Published in Gene Therapy Weekly, December 27th, 2001

CellExSys, a majority-owned subsidiary of Targeted Genetics Corp. (TGEN), has been issued U.S. Patent No. 6,316,257, "Modified Rapid Expansion Methods ("Modified-REM") for In Vitro Propagation of T Lymphocytes."

The patent broadly covers a commercial-scale process for generating antigen-specific T cells that may be used for therapeutic benefit or for a variety of drug development initiatives. Targeted Genetics' portfolio of cell therapy assets, including more than 70 patents and patent applications, are the foundation upon which CellExSys was established.

"This patent strengthens and extends the protection of our proprietary Rapid Expansion Method...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-12-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry